Daily Newsletter

11 August 2023

Share with colleague
Subscribe

Daily Newsletter

11 August 2023

Share with colleague
Subscribe

ChromaCode and Protean to launch assay for lung cancer in US

HDPCR is an advanced method for multiplexing biomarkers in a single, rapid assay across multiple sample types.

RanjithKumar Dharma August 11 2023

The HDPCR NSCLC assay delivers results within 24 hours. Credit: kalhh from Pixabay.

ChromaCode has entered a strategic partnership with Protean BioDiagnostic for the launch of a non-small cell lung cancer (NSCLC) assay in the US.

To be available through an early access programme, the assay leverages ChromaCode’s High Definition PCR (HDPCR) multiplexing technology.

Delivering results in under 24 hours, the HDPCR NSCLC assay can help identify all National Comprehensive Cancer Network (NCCN) recommended variants in one multiplexed assay.

It has been developed for very low concentrations, needing just 15 nanograms (ng) of input DNA and 5ng of RNA.

The assay showed more than 99% coverage of target genes and a 99% concordance with next-generation sequencing, making it a better option over biomarker testing, noted ChromaCode.

Protean president and CEO Anthony Magliocco said: “We value the rapid turnaround and clinically relevant markers of the HDPCR NSCLC assay. We see a real opportunity to collaborate with commercial payors, US Department of Veterans Affairs, and other government agencies, to establish coverage and reimbursement for this revolutionary technology.”

HDPCR is an advanced approach for multiplexing biomarkers in a single, rapid assay across multiple sample types.

Implemented on ChromaCode’s cloud-based analysis platform, the HDPCR technology is suitable for use in various applications including transplant, oncology, minimal residual disease and non-invasive prenatal testing.

ChromaCode chief business officer Padma Sundar said: “This partnership aligns with our mission to increase the availability of advanced diagnostic technologies, ensuring that medical laboratories have access to cutting-edge tools that can transform the landscape of cancer care.”

Latest news

FDA approves smaller height of Mobi-C artificial discs for cervical replacement

The newly approved 4.5mm artificial discs will give surgeons more flexibility in choosing the implant of best fit for patients.

11 August 2023

DermaSensor’s skin cancer detection device works on different skin tones

The breakthrough device has proved successful in studies, with the Miami medtech company now eyeing FDA approval.

11 August 2023

Acorai’s heart monitor receives FDA breakthrough device designation

Preliminary data from a study involving 281 out of 400 patients has supported the breakthrough device application.

11 August 2023

Telix doses first Chinese patient in prostate cancer imaging study

The study will enrol up to 110 patients who have biochemically recurrent prostate cancer.

11 August 2023

Motus GI secures approval in Israel for Pure-VuEVS System

The system helps physicians manage urgent or complex colonoscopies.

11 August 2023

Signal: Wave of layoffs in medical start-ups exposes underlying vulnerability

Babylon, Galera and more are cutting staff, serving as a reminder that failure is easy in the medical world.

11 August 2023

AI prompts wave of medical tourism

In the post-Covid landscape, artificial intelligence (AI) leverages calls for data analysis, targeted advertisements and optimal organisation within the medical tourism sector.

11 August 2023

Healthcare companies are hesitant to invest in the metaverse

The COVID-19 pandemic pushed the healthcare industry to rapid digitalization. Increased use of telehealth, telepresence systems, remote diagnostics, predictive AI, and wearable technology is changing how healthcare is delivered and improving patient outcomes. Emerging technologies such as AR and VR are becoming increasingly routine for professional training, surgical assistance, and treatment of psychological and neurological disorders. In the pharma and medical devices industries, AR, VR, and AI are rapidly accelerating drug discovery and manufacturing and generating supply chain efficiencies. New digital opportunities will look to build upon disruptive technologies. However, affordability is a limiting factor to widespread adoption. Per GlobalData estimates, the metaverse market is expected to grow at a CAGR of more than 33% between 2023 and 2030. Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns. Evidence of proven use cases and participation by a critical mass of users are imperative to drive a shift in metaverse investment.